COVID-19
Conditions
Keywords
Sars-CoV2, Aerosols, Infection transmission, Infection risk, Respiratory Tract Infections, Virus Diseases
Brief summary
In this study, a patient space occupied by a patient with confirmed COVID-19 in an open-space multiple bed area in the Intermediate Care Unit will be equipped with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing hospital policy infection prevention and control measures. The investigators are going to evaluate this intervention regarding its capacity to prevent the nosocomial onwards transmission of Sars-COV2 to patients located in the same multiple-bed open space patient area.
Detailed description
SARS-CoV-2 transmission includes a considerable amount of long-distance aerosol transmission. Ideal isolation is in single rooms. Isolation in special care multiple bed open-space patient areas (e.g. in the Intensive and Intermediate Care Unit) is set back to onsite isolation with distancing and ventilation as partial mitigation measures against nosocomial transmission. The investigators want to assess the effect of supplementation of existing room ventilation by means of an optimally placed mobile high efficiency particulate air (HEPA) filtration unit (Baldachin) in the ceiling area over confirmed COVID-19 infected patients on nosocomial onwards transmission to patients located in the same open-space multiple bed area. In order to quantify the effect, the investigators will determine the proportion of nosocomially infected individuals as assessed by nasopharyngeal swab on day 4 after the last exposure amongst all in the same room exposed patients in cardiovascular open-space Intermediate Care Unit rooms with Baldachin vs. open-space Intermediate Care Unit rooms without Baldachin.
Interventions
DEVICEBaldachin
Environmental intervention: Equipment of a patient space of a patient with confirmed COVID-19 in open-space multiple bed Intermediate Care Unit areas with a mobile, optimally placed high efficiency particulate air (HEPA)-equivalent air filtration unit (Baldachin) in addition to existing room ventilation and hospital policy infection prevention and control measures.
Sponsors
Insel Gruppe AG, University Hospital Bern
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
* Adult inpatients of included open-space IMC units with lab-confirmed SARS-CoV-2 infection, symptom onset or date of test ≤10 days prior inclusion.
Exclusion criteria
* Pregnancy, unability to give consent (e.g. informed consent form not available in patient language or non-judicious)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of nosocomially infected individuals within 4 days after exposure | 4 days after last exposure | Assessed by nasopharyngeal swab on day 4 after the last exposure amongst all in the same room exposed patients in cardiovascular open-space Intermediate Care Unit (IMC) rooms with the environmental interventions vs. open-space IMC rooms without the environmental intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of immunocompromised patients among those exposed | At the time of exposure | e.g. patients under treatment with steroids, chemotherapy |
| Preexisting air change rate per hour in the rooms where exposure occurs | At the time of exposure | — |
| Exposure duration | Period when exposed to a patient with confirmed COVID-19 in the same room | Expected to be on average hours up to a few days |
| Gender of exposed patients | At the time of exposure | As part of the demographic characteristics |
| Proportion of nosocomially infected patients within 10 days after exposure | 10 days after last exposure | As documented in the electronic patient record |
| Age of exposed patients | At the time of exposure | As part of the demographic characteristics |
Countries
Switzerland
Contacts
Primary ContactPhilipp Jent, MD
Backup ContactKarin J Grimm, MD
Outcome results
None listed